CG Oncology
CG Oncology developed cretostimogene, the oncolytic virus for early bladder cancer, and is filing for approval in 2026.
BOND-003 (BCG-unresponsive CIS), PIVOT-006 (intermediate-risk), CORE-008 (BCG-naive). IPO 2024.
Pages like this
not linked directly; found by shared links- TrialBOND-003
Shares Cretostimogene grenadenorepvec, Bladder & urothelial cancer.
- ProductNadofaragene firadenovec
Shares Oncolytic viruses that make interleukin-12 only inside the tumour, Bladder & urothelial cancer.
- TermBCG-unresponsive
Shares Cretostimogene grenadenorepvec, Bladder & urothelial cancer.
- TechnologyIntravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)
Shares Cretostimogene grenadenorepvec, Bladder & urothelial cancer.
- TechnologyOncolytic viruses
Shares Cretostimogene grenadenorepvec, Oncolytic viruses that make interleukin-12 only inside the tumour, Bladder & urothelial cancer.
- TechnologyCytokines & engineered cytokines
Shares Oncolytic viruses that make interleukin-12 only inside the tumour, Bladder & urothelial cancer.